Form 4: Acrivon CEO, EVP report RSU tax share withholdings

Acrivon insiders reported shares withheld to cover taxes upon RSU vesting, with the CEO remaining a significant holder.

Summary

• On 11/14/2025, CEO Peter Blume-Jensen had 59,765 shares withheld (code F) at $2.24 per share to satisfy tax obligations upon RSU vesting.
• EVP Kristina Masson had 490 shares withheld (code F) at $2.24 per share to satisfy tax obligations upon RSU vesting.
• Post-transaction holdings: Blume-Jensen directly holds 2,066,675 shares; 314,706 additional shares are held by spouse Dr. Masson, which he disclaims except to the extent of his pecuniary interest.
• Form filed by more than one reporting person, with signatures dated 11/18/2025.
• Both insiders are officers and directors of Acrivon Therapeutics, Inc. (Ticker: ACRV).

Sentiment

Score: 5

Explanation: Administrative RSU tax withholdings with no open-market selling; insider ownership remains substantial.

Positives

• Transactions were administrative tax withholdings on RSU vesting (code F), not open-market sales.
• Significant insider ownership remains: CEO holds 2,066,675 shares directly; spouse holds 314,706 shares.
• Clear disclosure of spousal holdings and beneficial ownership disclaimers.

Negatives

• Minor reduction in insider share counts due to shares withheld for taxes.
• Insider dispositions may be perceived negatively by some investors despite being administrative.

Future Outlook

No guidance or forward-looking statements provided.

Management Comments

• Shares were withheld by the issuer to satisfy mandatory tax withholding upon vesting of restricted stock units.

Industry Context

Routine RSU tax-withholding entries by executives are common across biotech and broader public markets and are typically neutral signals regarding insider sentiment.

Comparison to Industry Standards

• Consistent with standard practice at peer biopharma companies (e.g., Moderna, Regeneron, Gilead) where RSU vesting triggers code F withholding transactions rather than open-market sales.
• Use of fair market value at vesting (here, $2.24) to determine withholding aligns with common U.S. equity compensation practices.
• Beneficial ownership disclaimers for spousal holdings are standard under Section 16 reporting norms.

Stakeholder Impact

• Minimal impact to shareholders as transactions reflect tax withholding, not discretionary selling.
• No effect on company cash; no capital raised or spent.
• Transparency on insider and spousal holdings supports governance clarity.

Key Dates

Keywords

Acrivon Therapeutics, ACRV, Form 4, insider transaction, beneficial ownership, restricted stock units, RSU vesting, tax withholding, Peter Blume-Jensen, Kristina Masson, biotech